Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00

Viridian Therapeutics (NASDAQ:VRDN) had its price objective lowered by Needham & Company LLC from $42.00 to $32.00 in a research report report published on Monday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. UBS Group started coverage on shares of Viridian Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price for the company. Evercore reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Wedbush reiterated an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen cut shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Trading Down 2.1%

Shares of NASDAQ:VRDN opened at $19.15 on Monday. The company has a market capitalization of $1.96 billion, a PE ratio of -5.82 and a beta of 1.16. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $34.29. The business’s fifty day simple moving average is $28.90 and its 200-day simple moving average is $27.83.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. As a group, equities research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. MetLife Investment Management LLC lifted its holdings in shares of Viridian Therapeutics by 0.8% during the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock worth $1,369,000 after purchasing an additional 356 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Viridian Therapeutics by 0.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock worth $4,337,000 after buying an additional 380 shares during the period. US Bancorp DE raised its position in Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares during the last quarter. Finally, Virtus Investment Advisers LLC lifted its stake in Viridian Therapeutics by 13.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock valued at $256,000 after acquiring an additional 971 shares during the period.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Company reported positive topline results from the Elegrobart Phase 3 REVEAL‑1 trial in active thyroid eye disease — the clinical readout is a fundamental positive for long‑term drug value and commercial potential. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and set a $22 target while revising Q1–Q4 and FY2026 EPS estimates (small mix of raises and cuts) — shows continued analyst support but revised modeling reflects higher near‑term costs/assumptions. HC Wainwright estimate and rating note
• Neutral Sentiment: Recent intraday swings included a sharp bounce the prior session (Zacks noted a 5.6% jump on higher‑than‑average volume), highlighting that VRDN is trading on headline events and momentum as much as fundamentals. Viridian Therapeutics (VRDN) Soars 5.6%
• Negative Sentiment: Shares plunged pre‑market on headlines that followed the Phase 3 disclosure (market reaction suggests investors were disappointed by details beyond topline, or that expectations were higher), triggering heavy selling and volatility. VRDN stock plummeted 41% pre-market today
• Negative Sentiment: Multiple firms trimmed price targets (Goldman Sachs to $36, Wells Fargo to $20 with an equal‑weight, Wedbush to $37, HC Wainwright down to $22) — these cuts signal reduced near‑term upside in sell‑side models and likely contributed to downward pressure. Broker price target updates
• Negative Sentiment: Several news outlets highlighted that shares fell despite the positive topline, suggesting investor concerns about safety details, subgroup results, magnitude of benefit, or commercial assumptions — expect continued headline‑driven trading until full data and guidance are clarified. Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.